Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
GERMANTOWN, Md., June 10, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsi
Precigen to Present at the JMP Securities Life Sciences Conference
04:05pm, Thursday, 10'th Jun 2021
GERMANTOWN, Md,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
Precigen Reports First Quarter 2021 Financial Results
04:30pm, Monday, 10'th May 2021
GERMANTOWN, Md., May 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen Announces Departure of Chief Financial Officer
04:05pm, Tuesday, 30'th Mar 2021
GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, tod
GERMANTOWN, Md., March 23, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, tod
GERMANTOWN, Md., March 18, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, tod
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript
12:39am, Tuesday, 02'nd Mar 2021
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
07:43pm, Monday, 01'st Mar 2021
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and -16.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know
01:42pm, Monday, 22'nd Feb 2021
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Troll-able Stocks That Could Be the Next GME
10:55am, Wednesday, 17'th Feb 2021
The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPla
10 Short Squeeze Candidates Under $10
08:36am, Saturday, 30'th Jan 2021
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
04:05pm, Tuesday, 26'th Jan 2021
GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
08:05am, Friday, 22'nd Jan 2021
GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offerin
Precigen Announces Proposed Public Offering of Common Stock
04:01pm, Thursday, 21'st Jan 2021
GERMANTOWN, Md., Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen inten
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:05am, Wednesday, 06'th Jan 2021
GERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p
